On the morning of October 30, Ma Xin, member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, performed an inspection ofJiangsu Hansoh, a subsidiary of Hansoh Pharma. Yang Xinchong, Secretary-General of the provincial government, Shen Jianrong, Director of the Jiangsu Development and Reform Commission, and Tang Libin, Director of the Jiangsu Securities Regulatory Bureau, participated in the inspection. Ma Shiguang, Secretary of the Lianyungang Municipal Party Committee, joined in the visit. Lyu Aifeng, Executive Director of Hansoh Pharma, hosted the visit and provided a brief on the company’s current innovation and development achievements.
Ma Xin (third from left) performing an inspection at Jiangsu Hansoh
Ma Xin and his delegation conducted a detailed investigation into the company's latest developments in production, operations, and innovation research. According to Lyu Aifeng, relying on an internationally leading innovative technology platform and a global R&D team of over 1,700 people, Hansoh Pharma efficiently advances its promising R&D pipeline. Currently, over 30 innovative drugs are undergoing more than 50 clinical trials. Several products have the potential to be first-in-class (FIC) or best-in-class (BIC). Seven innovative drugs that have been marketed and their corresponding nine indications are included in the national medical insurance catalog. While focusing on independent research and development, the company expedites cooperation on global innovation. It has introduced a total of 11 collaborative projects and completed two ADC product out-licensing deals. Among them, HS-20093 (B7-H3 ADC) hasbeen designated as breakthrough therapy by the FDA.
After listening to the introduction, Ma Xin affirmed the company's continuous increase in research and development investment, strengthening the breakthrough of key technologies, and promoting innovation transformation. He encouraged the company to actively explore the frontiers of global biotechnology and hasten the development and transformation of innovative technologies and products so that patients can benefit from more new drugs and good drugs.
